Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189770 | 0.79 | CYP3A4 (0.60) | CYP3A4MAOBMPO | |
| SCHEMBL19783575 | 0.79 | CYP3A4 (0.60) | CYP3A4MAOBMPO | |
| SCHEMBL21395966 | 0.78 | CYP3A4 (0.52) | CYP3A4MAOBMPOMGAMGAA | |
| SCHEMBL23628947 | 0.78 | TOP2A (0.55) | CYP3A4MPO | |
| SCHEMBL23628946 | 0.77 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL23629003 | 0.77 | CYP2C19 (0.55) | CYP3A4 | |
| SCHEMBL23628929 | 0.74 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL20305445 | 0.74 | CYP3A4 (0.60) | CYP3A4MAOBMGAMGAASI | |
| SCHEMBL19900619 | 0.73 | CYP3A4 (0.43) | CYP3A4GAA | |
| SCHEMBL29752153 | 0.72 | CYP3A4 (0.68) | CYP3A4MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | UNIVERZA V LJUBLJANI (SI) | 2025-03-25 | — | — | US | disclosed |
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | UNIVERZA V LJUBLJANI (SI) | 2021-10-21 | — | — | US | disclosed |
| EP-3847172-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | Univerza v Ljubljani (SI) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323957-A1 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOP1, TOP2A, TOP2B | CYP3A4 643/4885MAOB 1631/4885MPO 165/4885 |
| US-12258342-B2 | Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria | TOP1, TOP2A, TOP2B | CYP3A4 587/4885MAOB 1415/4885MPO 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.